IVF In Animals Market Generated Opportunities, Future Scope
Coherent Market Insights has published a report titled "IVF In Animals Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033". The report details market competition, geographic distribution, growth potential, industry performance, and key success factors. Leading players include Zoetis, Merck Animal Health, and Elanco Animal Health, with segmentation covering various animal types.
Harbor Capital Advisors Inc. Sells 49,302 Shares of Elanco Animal Health Incorporated $ELAN
Harbor Capital Advisors Inc. has reduced its stake in Elanco Animal Health Incorporated by 32.2%, selling 49,302 shares and retaining 103,761 shares valued at $2.35 million. Despite this sale, Wall Street sentiment remains largely positive with a "Moderate Buy" consensus and an average target price of $27.67, following Elanco's strong Q4 earnings beat and optimistic Q1/FY2026 guidance. Institutional investors hold 97.48% of the stock, signifying strong confidence.
ELAN Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Elanco Animal Health Inc (ELAN). It indicates a "Strong Sell" consensus based on various technical indicators, including moving averages and oscillators. Key metrics like MACD and RSI are discussed, along with support and resistance levels for ELAN stock.
ELAN PE Ratio & Valuation, Is ELAN Overvalued
Elanco Animal Health Inc (ELAN) is currently in the "Fair" valuation zone, with its forward PE ratio of 21.41 fairly comparable to its five-year average of 18.89. The fair price for ELAN, according to a relative valuation method, ranges between 20.59 to 30.91. While its P/B ratio is higher than its 3 and 5-year averages, its current FCF yield is lower compared to these averages.
Elanco (ELAN) director defers fees into 600 Deferred Stock Units
Elanco Animal Health Inc. director K. Anand deferred her cash retainer fees, opting to receive 600.7104 Deferred Stock Units. These units, valued at $23.93 per share on the grant date (March 31, 2026), are economically equivalent to common stock and will be settled in shares upon her separation from the Board. Following this transaction, Ms. Anand holds a total of 9,495.4518 Deferred Stock Units.
Chewy reaches settlement in Elanco flea and tick antitrust litigation
Chewy has settled its portion of a high-stakes antitrust lawsuit against Elanco Animal Health Inc. and other major pet supply retailers. The lawsuit alleges that Elanco paid retailers to block generic versions of the Advantix flea and tick medication, artificially inflating prices. While Chewy is withdrawing from the litigation, the case will continue against Elanco and the remaining retail defendants.
Elanco Animal Health Inc (ELAN) Shares Gap Down to $23.21 on Mar 27
Elanco Animal Health Inc (ELAN) shares dropped 5.57% on March 27, reaching an intraday low of $23.09 before closing at $23.21. This places the stock 16.27% below its 52-week high, while still 189.40% above its 52-week low. Analyst forecasts show an average target price of $29.58, indicating a potential upside of 27.46%, with a consensus "Outperform" rating, although GuruFocus estimates a fair value of $15.19, suggesting a downside of 34.55%.
Vanguard reports 0 shares of Elanco after realignment (NYSE: ELAN)
The Vanguard Group has filed a Schedule 13G/A, reporting 0 shares of Elanco Animal Health Inc. common stock following an internal realignment on January 12, 2026. This realignment means certain Vanguard subsidiaries now report beneficial ownership separately, as confirmed by Ashley Grim, Head of Global Fund Administration. The filing indicates Vanguard no longer directly holds or is deemed to beneficially own these shares.
Elanco (ELAN) Jumps 19.7% to Record High on Earnings Boost
Elanco (ELAN) stock surged by 19.7% to a record high following a positive earnings report. The company's strong financial performance appears to have driven significant investor confidence, leading to the substantial increase in its share price. This jump indicates a favorable market reaction to Elanco's latest financial results.
Elanco Gets Investors’ Dog Itch Drug Development Suit Dismissed
A federal judge dismissed a proposed class-action lawsuit against Elanco Animal Health Inc., which alleged the company hid a study that would delay regulatory approval of its canine itch treatment, Zenrelia. Investors claimed Elanco failed to disclose a study on the drug's effect on canine vaccination responses, but the court found insufficient evidence that the company or its executives knowingly misled investors. The dismissal was without the ability for investors to replead their case.
Syngulon announces licensing agreement with Elanco Animal Health
SYNGULON SRL, a biotechnology company, has announced a worldwide licensing agreement with Elanco Animal Health Incorporated. This agreement grants Elanco access to Syngulon's proprietary bacteriocin-based microbial selection technologies for developing and manufacturing animal health products. The technology aims to enhance microbial stability and efficiency in industrial fermentation, supporting the production of recombinant proteins and plasmid DNA.
Elanco (ELAN) CFO receives 8.216 deferred stock units as compensation award
Elanco Animal Health's EVP and CFO, Robert M. VanHimbergen, received a grant of 8.216 deferred stock units as part of a compensation award. These units are linked to Elanco common stock and will settle in cash or stock upon his employment termination or in a specified future year, as per the company's Executive Deferral and Stock Match Plan. This transaction is a compensation award and not an open-market trade, increasing his reported deferred stock unit balance to 48.7929 units.
Elanco (ELAN) CEO receives deferred stock units in compensation grant
Elanco Animal Health Inc. CEO, Jeffrey N. Simmons, received a grant of 117.887 deferred stock units on March 20, 2026, as part of his compensation. These units represent the right to receive Elanco common stock or its cash equivalent, bringing his total direct holdings to 23,795.2703 deferred stock units. The units will settle in cash or shares after his employment ends or in a specified future year, according to the company's Executive Deferral and Stock Match Plan.
Elanco (NYSE: ELAN) executive receives new deferred stock unit grant
Rajeev A. Modi, an executive at Elanco Animal Health Inc. (NYSE: ELAN), was granted 61.5901 deferred stock units as part of the company's Executive Deferral and Stock Match Plan. These units, which represent the right to receive common stock or cash, will settle after his employment ends or in a specified future year. Following this grant, Modi beneficially owns a total of 9,072.9178 deferred stock units.
ELAN Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial analysis of Elanco Animal Health Inc (ELAN), detailing its revenue breakdown, profitability margins, and a comparison with competitors. Elanco generates a significant portion of its revenue from Farm Animal products, and while it maintains a gross margin of 39.34%, its net margin is negative at -24.13%. The analysis benchmarks ELAN against industry leaders SMMT and NBIX to assess its market position and financial performance.
New Mexico Educational Retirement Board Invests $2 Million in Elanco Animal Health Incorporated $ELAN
The New Mexico Educational Retirement Board recently acquired 99,200 shares, valued at approximately $1.998 million, of Elanco Animal Health Incorporated ($ELAN) in the third quarter, indicating renewed institutional interest. Several analysts have upgraded their ratings for Elanco, resulting in a "Moderate Buy" consensus and an average target price of $27.67. Elanco also reported strong Q3 earnings, beating analyst estimates with an EPS of $0.13 and revenue of $1.14 billion, and provided positive FY2026 guidance.
Elanco Animal Health Inc (ELAN) Shares Down 3.01% on Mar 20
Shares of Elanco Animal Health Inc (ELAN) dropped 3.01% in mid-day trading on March 20th, reaching an intraday low of $24.23 before closing at $24.37. This places ELAN 12.10% below its 52-week high but 203.80% above its 52-week low. Analyst forecasts suggest an average target price of $29.58, implying a 21.42% upside, however, GuruFocus estimates a GF Value of $15.19, indicating a potential 37.66% downside.
Elanco Animal Health (ELAN) surges 7.6%: Is this an indication of further gains?
Elanco Animal Health (ELAN) saw its stock surge by 7.6%, outperforming the S&P 500's gain of 0.2% on what was a positive trading day for the broader market. This significant upward movement raises the question of whether the company is poised for additional stock price increases in the near future. Investors will be keen to observe if this momentum continues in the upcoming trading sessions.
Former Elanco director joins ImmuCell board in calf-health push
ImmuCell (Nasdaq: ICCC) has appointed Kathy Turner, a former director at Elanco Animal Health with over 30 years of global commercial leadership experience, to its Board of Directors, effective April 1, 2026. She will replace Steven Rosgen and chair the Compensation and Stock Option Committee while also serving on the Audit Committee. Turner's extensive background is expected to bolster ImmuCell's efforts to expand the reach of its First Defense® product line internationally.
ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board
ImmuCell Corporation has appointed Kathy Turner to its Board of Directors, effective April 1, 2026. Ms. Turner, who previously served on the Board of Elanco Animal Health and held leadership roles at IDEXX Laboratories and Abbott Laboratories, brings extensive global animal health experience. She will replace the retiring Steven Rosgen and chair the Compensation and Stock Option Committee, as well as serve on the Audit Committee.
Elanco Animal (ELAN) Climbs 7.6% on Upbeat Outlook, Sets Sights on AI
Elanco Animal Health Inc. (NYSE:ELAN) saw its stock climb 7.6% after presenting an upbeat outlook for the year at the KeyBanc Capital Markets Healthcare Forum. The company plans to leverage AI and pursue M&A to grow organic revenues by 4-6% and adjusted EBITDA by 8%, despite a net loss in the previous year. This strategic shift towards AI aims to drive future growth and investor confidence.
Animal Health Market size to reach $199.1 Billion by 2035 | Key
The animal health market is projected to grow from approximately $70.7 billion in 2025 to $199.1 billion by 2035, driven by evolving farming practices, veterinary services, and consumer preferences. North America is expected to dominate, while Asia Pacific will see the fastest growth. Key trends include digitalization, the rise of companion animal care, and a focus on preventive healthcare, with major players like Zoetis and Merck Animal Health making strategic advancements.
Elanco jumps as investors focus on upbeat 2026 outlook after strong Q4 results
Elanco Animal Health Incorporated (ELAN) saw a 7.6% stock increase following its Q4 2025 results and positive 2026 guidance. Investors are reportedly optimistic about improved operational execution, margin expansion, and scaling new products, supported by management's productivity program. This bullish sentiment is further fueled by recent momentum and strong insider buying, despite some institutional investors reducing their stakes.
CSM Advisors LLC Takes Position in Elanco Animal Health Incorporated $ELAN
CSM Advisors LLC has acquired a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) during the 3rd quarter, purchasing 63,540 shares valued at approximately $1.278 million. Other institutional investors have also increased their holdings in Elanco, collectively owning 97.48% of the company's stock. The article details Elanco's financial performance, including its recent earnings beat and current stock metrics, alongside recent analyst upgrades and price target revisions.
Cinctive Capital Management LP Reduces Holdings in Elanco Animal Health Incorporated $ELAN
Cinctive Capital Management LP significantly reduced its stake in Elanco Animal Health Incorporated by 53.8% in the third quarter of 2025, selling 137,675 shares and retaining 118,239 shares valued at $2.38 million. Despite this reduction from one hedge fund, other institutional investors like Primecap Management Co. CA, Vanguard Group Inc., Dimensional Fund Advisors LP, UBS Group AG, and Brandes Investment Partners LP increased their holdings in Elanco Animal Health, which now has an average rating of "Moderate Buy" from analysts. The company reported earnings above consensus and has positive financial guidance for Q1 and FY 2026.
Integral Health Asset Management LLC Grows Stake in Elanco Animal Health Incorporated $ELAN
Integral Health Asset Management LLC significantly increased its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 128.6% in the third quarter, now owning 800,000 shares valued at $16.11 million. This makes Elanco 1.1% of the fund's portfolio. The company has received a "Moderate Buy" rating from analysts with an average price target of $27.67, and recently beat quarterly earnings expectations, issuing positive guidance for Q1 and FY 2026.
Private Management Group Inc. Cuts Stock Position in Elanco Animal Health Incorporated $ELAN
Private Management Group Inc. significantly reduced its stake in Elanco Animal Health by 37.5% in the third quarter of 2025, selling over 965,000 shares. Despite this, analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $27.67, driven by strong Q3 earnings that surpassed expectations. The company also provided optimistic guidance for fiscal year 2026.
Van ECK Associates Corp Cuts Stock Holdings in Elanco Animal Health Incorporated $ELAN
Van ECK Associates Corp reduced its stake in Elanco Animal Health Incorporated by 9.0% in Q3, selling 78,736 shares and holding 798,456 shares valued at $16.08 million. Other hedge funds made smaller adjustments, and institutional investors collectively own 97.48% of the company. Elanco Animal Health has a "Moderate Buy" consensus rating from analysts with an average price target of $27.67, and recently beat Q3 earnings expectations.
Elanco Stock Analysis: Strong Gains Mask Revenue, Margin Concerns | 2026 - News and Statistics
Elanco Animal Health's stock has seen significant gains, rising 26.6% in six months and outperforming the S&P 500. However, analysts are concerned about the company's underlying business quality, pointing to decelerating revenue growth and declining operating margins. Coupled with a negative five-year average return on invested capital and a forward price-to-earnings multiple of 23, these fundamental issues suggest potential downside risks despite recent stock performance.
Barrow Hanley Mewhinney & Strauss LLC Sells 2,592,747 Shares of Elanco Animal Health Incorporated $ELAN
Barrow Hanley Mewhinney & Strauss LLC significantly reduced its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by selling over 2.5 million shares, bringing their total ownership to about 1.01% with a value exceeding $101 million. This reduction comes amidst other institutional investors either increasing or decreasing their positions in the animal health company. Despite the institutional selling, company insiders, including a director and the CEO, recently purchased substantial amounts of shares, indicating internal confidence.
UBS maintains Buy on ELAN (Elanco Animal Health Incorporated) March 2026
UBS has re-affirmed its Buy rating for Elanco Animal Health Incorporated (ELAN) on March 10, 2026, citing a "catalyst-rich" outlook for the company's revenue and margin growth throughout 2026. Despite no new price target being issued, the maintained rating signals UBS's continued confidence in ELAN's product pipeline and cost discipline. This affirmation comes amidst a -2.37% intraday stock dip, highlighting a divergence between analyst sentiment and immediate market reaction.
Elanco (NYSE: ELAN) CFO receives deferred stock unit award
Elanco Animal Health's (NYSE: ELAN) CFO, Robert M. VanHimbergen, was granted 9.485 deferred stock units, increasing his total direct holding of this award type to 40.5769 units. These units are compensation awards tied to Company common stock, with each unit representing the right to receive one share or its cash equivalent upon termination of employment or in a specified future year, as per the Executive Deferral and Stock Match Plan. This transaction, detailed in an SEC Form 4 filing, is a compensation grant and not an open-market stock purchase or sale.
Elanco (ELAN) executive receives grant of 1,360 deferred stock units
Elanco Animal Health executive Rajeev A. Modi was granted 1,360.2363 deferred stock units, valued at $23.36 per unit, as compensation. This grant increased his total directly held deferred stock units to 9,011.3277. The units, representing the right to receive Elanco common stock or cash equivalent, will settle after employment termination or in a specified future year, per the company’s Executive Deferral and Stock Match Plan.
Elanco (NYSE: ELAN) officer receives new deferred stock unit grant
Elanco officer Correia de Simas Jose Manuel received a grant of 17,637.8425 deferred stock units, increasing his total holdings to 22,280.4709 units. These units, valued at $23.36 each, represent the right to receive company common stock or cash equivalent and will settle upon employment termination or a specified future year under the Executive Deferral and Stock Match Plan. This transaction was reported in an SEC Form 4 filing and is compensation-related, not an open-market purchase or sale.
Livestock Pharmaceutical Sales Still Booming Despite Public Health Concerns
Elanco Animal Health reported strong quarterly revenue, with its farm animal sector increasing 17% year-over-year, despite growing public health concerns about antimicrobial resistance (AMR). The company's stock rose favorably after new antibiotic sales. Critics argue against the overuse of antibiotics in livestock, which contributes to AMR, and suggest alternative strategies like improved animal welfare to mitigate disease spread.
Citigroup Inc. Cuts Stake in Elanco Animal Health Incorporated $ELAN
Citigroup Inc. significantly reduced its stake in Elanco Animal Health Incorporated by 75.5% in the third quarter of 2025, selling 344,563 shares and leaving it with 112,058 shares valued at $2.26 million. Despite this, company insiders, including Director Lawrence Kurzius and CEO Jeffrey N. Simmons, increased their holdings through recent stock purchases. Elanco Animal Health recently surpassed EPS and revenue estimates and holds a "Moderate Buy" consensus rating with a target price of $27.67.
Teachers Retirement System of The State of Kentucky Purchases Shares of 110,000 Elanco Animal Health Incorporated $ELAN
The Teachers Retirement System of The State of Kentucky recently acquired a new position of 110,000 shares in Elanco Animal Health Incorporated (NYSE:ELAN), valued at approximately $2.215 million. This purchase reflects increasing institutional interest, as other hedge funds have also modified their holdings in the company. Elanco maintains a "Moderate Buy" consensus rating from analysts, with recent upgrades to price targets, and reported strong Q3 earnings, beating analyst estimates.
Injected Veterinary Pain Management Drugs Market Set to Witness Rapid Growth Through 2033 | Zoetis Inc., Elanco Animal Health Incorporated
Coherent Market Insights has released a detailed report on the "Injected Veterinary Pain Management Drugs Market," forecasting rapid growth through 2033. The report provides an in-depth analysis of market trends, challenges, opportunities, competitive dynamics, and regional performance, featuring key players like Zoetis Inc. and Elanco Animal Health Incorporated. It aims to serve as a crucial decision-support tool for industry stakeholders, covering critical success factors, risk assessment, and financial analysis.
Picton Mahoney Asset Management Invests $7.49 Million in Elanco Animal Health Incorporated $ELAN
Picton Mahoney Asset Management has invested $7.49 million in Elanco Animal Health Incorporated, acquiring 372,140 shares during the third quarter, representing about 0.07% of the company. Elanco exceeded quarterly earnings expectations, reporting an EPS of $0.13 on $1.14 billion revenue, and provided positive Q1 and full-year 2026 guidance. This investment, alongside increased insider buying and raised price targets from analysts, signals growing confidence in the animal health company.
Elanco (ELAN) CAO reports RSU grants and tax-withholding share disposal
Elanco Animal Health's Chief Accounting Officer, James M. Meer, reported receiving restricted stock units (RSUs) and disposing of shares for tax withholding purposes. He was granted 9,596 and 5,209 shares as RSUs, with a stated price of $0.00 per share, and disposed of 4,787 shares at $26.40 per share to cover tax liabilities. The RSUs will vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Elanco (ELAN) executive logs new stock grants and tax withholding share disposal
Elanco Animal Health executive Jose Manuel Correia de Simas reported several equity compensation movements, including grants of employee stock options, deferred stock units, and restricted common stock. Concurrently, he disposed of 9,883 shares of common stock at $26.40 per share to cover tax obligations, which was a tax-withholding disposition rather than an open-market sale. The grants are subject to a multi-year vesting schedule, with portions vesting annually from March 2027 to March 2029, and deferred units vesting in December 2027.
Elanco Animal Health Incorporated $ELAN Shares Sold by Black Creek Investment Management Inc.
Black Creek Investment Management Inc. significantly reduced its stake in Elanco Animal Health (NYSE:ELAN) by 35.2% during the third quarter, selling over 6.7 million shares, though it remains a substantial holding in their portfolio. Despite this institutional sell-off, Elanco reported strong quarterly earnings, beating analyst estimates, and provided positive guidance for Q1 and FY2026. Company insiders, including CEO Jeffrey Simmons, have been net buyers of the stock, acquiring 43,450 shares in the last 90 days.
Elanco Animal Health (NYSE: ELAN) officer uses 4,392 shares for tax withholding
Rajeev A. Modi, an officer at Elanco Animal Health Inc (NYSE: ELAN), disposed of 4,392 shares of common stock on March 3, 2026, for tax withholding purposes. The disposition was made at a price of $24.88 per share, leaving him with 155,901 directly owned shares. This transaction is classified as a tax-related share disposition rather than an open-market sale.
Elanco (ELAN) officer granted options, RSUs and tax share disposition
Elanco Animal Health officer Ellen de Brabander reported changes in her equity compensation, including the grant of 51,819 employee stock options and 92,924 shares of common stock, all at a price of $0.00 per share. Additionally, 46,278 shares were disposed of at $26.40 per share to cover tax obligations. Both the restricted stock units and stock options are set to vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
[Form 4] Elanco Animal Health Inc Insider Trading Activity
Elanco Animal Health Inc.'s general counsel, Shiv O'Neill, reported insider trading activity involving equity compensation. On March 1, 2026, O'Neill received 29,993 stock options and 33,087 shares of common stock, along with an additional grant of 14,679 common shares. A disposition of 13,111 common shares at $26.40 each occurred to cover tax obligations.
Elanco (ELAN) CFO VanHimbergen receives new stock and option grants
Robert M. VanHimbergen, EVP and CFO of Elanco Animal Health (ELAN), received grants of 48,375 employee stock options and 23,675 shares of common stock. These awards, part of his compensation, will vest in equal parts over three years, on March 1, 2027, March 1, 2028, and March 1, 2029. Following these grants, VanHimbergen's direct beneficial ownership in Elanco common stock totals 148,652 shares.
Royce & Associates LP Buys 105,632 Shares of Elanco Animal Health Incorporated $ELAN
Royce & Associates LP has increased its stake in Elanco Animal Health Incorporated by 21.3%, acquiring an additional 105,632 shares to now hold 602,564 shares, valued at approximately $12.14 million. This move comes as institutional investors collectively own about 97.48% of the company. Insider buying by CEO Jeffrey N. Simmons and CFO Robert M. Vanhimbergen also occurred recently, with the company beating revenue and EPS estimates and providing positive Q1 and FY 2026 guidance.
Elanco Animal Health (ELAN) Stock Analysis: Navigating a 8.97% Potential Upside in the Booming Animal Health Market
Elanco Animal Health (ELAN) is a prominent player in the animal health sector, offering various products for pets and farm animals. Despite a negative return on equity, the company shows strong revenue growth and a healthy free cash flow, with analysts projecting an 8.97% potential upside. With a supportive technical outlook and a strong product portfolio, Elanco is positioned as an attractive opportunity for investors in the expanding animal health market.
TD Asset Management Inc Has $21.87 Million Stock Holdings in Elanco Animal Health Incorporated $ELAN
TD Asset Management Inc significantly increased its stake in Elanco Animal Health (NYSE:ELAN) by 289% in Q3, holding 1,085,823 shares valued at $21.87 million. The company recently beat earnings estimates, reporting $0.13 EPS and $1.14 billion revenue, and analysts maintain a "Moderate Buy" rating with a $27.67 target price. Insider buying activity has also been noted, with company insiders acquiring 43,450 shares in the last 90 days.
Elanco Animal Health (ELAN) Is Up 5.7% After Beating Q4 Views And Raising 2026 Innovation Outlook
Elanco Animal Health (ELAN) saw its stock rise by 5.7% after exceeding Q4 revenue and adjusted earnings expectations and raising its 2026 innovation revenue outlook. Despite reporting a net loss for the quarter and full year, the company highlights its strong product pipeline with new approvals and acquisitions. The refreshed investment narrative focuses on Elanco's innovation-driven turnaround and its ability to achieve sustainable growth amidst execution risks and competitive pressure.
